Wed, Sep 17, 2014, 11:02 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

bioimmunomabman 348 posts  |  Last Activity: 6 hours ago Member since: Nov 10, 2004
  • Reply to

    PUMA Phase 3 Success

    by biotechbeagle Jul 23, 2014 10:58 AM
    bioimmunomabman bioimmunomabman Jul 23, 2014 3:54 PM Flag

    I had similar thoughts, maybe more puts, or put spread. These results are not as good as Kadcyla as far as I can tell and Kad+Pert should blow them away. We own a diseased turtle, not a puma!

  • Reply to

    Belviq's New Application?

    by lfyoung59 Jul 22, 2014 9:25 PM
    bioimmunomabman bioimmunomabman Jul 22, 2014 10:47 PM Flag

    is it the drug, or the loss of weight that helps sleep???

  • bioimmunomabman by bioimmunomabman Jul 22, 2014 9:15 AM Flag

    Before TSC apparently deleted and replaced the article below with the perilous reversal article, someone working for TSC wrote this positive technical article below calling for $14's. TSC pumped and dumped all in one day. AF must have noticed the positive article and told them to retract it because his clients were angry.

    From "The Street" 3 bios breaking out on big volume
    ImmunoGen (IMGN), a biotechnology company, develops targeted anticancer therapeutics. This stock closed up 8.8% to $11.74 in Friday's trading session.

    Friday's Volume: 3.82 million
    Three-Month Average Volume: 924,583
    Volume % Change: 354%

    From a technical perspective, IMGN surged sharply higher here right above its 52-week low of $10.65 with monstr upside volume. This sharp spike to the upside on Friday is quickly pushing shares of IMGN within range of triggering a near-term breakout trade. That trade will hit if IMGN manages to take out its 50-day moving average of $10.82 to some more near-term overhead resistance levels at $12 to $12.17 with high volume.

    Traders should now look for long-biased trades in IMGN as long as it's trending above its 52-week low of $10.65 and then once it sustains a move or close above those breakout levels with volume that hits near or above 924,583 shares. If that breakout triggers soon, the IMGN will set up to re-fill more of its previous gap-down-day zone from June that started at $13.78. If that gap gets filled with volume, then IMGN could easily tag its next major overhead resistance levels at its 200-day moving average of $14.33 to $14.80.

  • Reply to


    by sharonconk Jul 18, 2014 8:28 AM
    bioimmunomabman bioimmunomabman Jul 21, 2014 6:53 PM Flag

    I sent CA an email today, they need to put a professional hedge on this position if possible, or just sell it for cash. If they do another secondary, I am out for good.

  • bioimmunomabman bioimmunomabman Jul 21, 2014 4:49 PM Flag

    not sure it will have any effect on Europe, but certainly is a huge plus in Israel, which I am sure is a very small market. It's a small win.

  • bioimmunomabman by bioimmunomabman Jul 21, 2014 4:47 PM Flag

    Hey moron #$%$, and don't make illegal, false statements about liquidity. You are not an auditor and have no clue what you are talking about. ARNA could cut costs and run for years on their current cash levels. You short liars should all be put in jail. How do you live with yourself trying to run down a business, mislead people...Can't you get a real job and add some value to society. Thou shall not bare false witness! I guess we are supposed to forgive #$%$ like you, but it's getting real old.

  • Reply to

    A couple of notes about insider transactions

    by tagetlocman Jul 17, 2014 9:31 AM
    bioimmunomabman bioimmunomabman Jul 21, 2014 1:46 PM Flag

    They all do this Biotech CEO=ATM and no concern for shareholders. They all think they own the company and their Boards and large shareholders do nothing to stop them. It's wrong and needs to change.

  • Reply to

    Insider transactions....;)

    by crecy_war_knight Jul 19, 2014 11:52 PM
    bioimmunomabman bioimmunomabman Jul 21, 2014 1:42 PM Flag

    BB's own so many shares, there's only one way for them to exit, acquisition. By any other means and the share price gets halved immediately after the first form 4. Recent hiring of CFO puts the exit out much further, so now we are at the mercy of management to get the filing right the first time. On the + side, it appears FDA wants the drug approved. On the - side, small biotech's are prone to making stupid mistakes on their first filing. I sure hope they GIRTFT.

  • bioimmunomabman bioimmunomabman Jul 21, 2014 1:36 PM Flag

    sure and I could live long enough to see a return on my investment, sale of the company, or additional dilution. Which will come first is the question. Upper left to lower right pattern is getting OLD!!!

  • Reply to


    by josef.novak Jul 21, 2014 11:20 AM
    bioimmunomabman bioimmunomabman Jul 21, 2014 12:24 PM Flag

    ARNA needs to show success in smoking cessation, or great weight loss gains with phen, or the losses could continue. I am becoming concerned, based on the stock's performance and the ability of shorts to exit while the price continues to decline.

  • bioimmunomabman by bioimmunomabman Jul 21, 2014 10:04 AM Flag

    It's just amazing, uncanny, even suspicious, their ability to time exec stock option grants at a 2-year low just a few months after their uncanny ability to sell high. How do they do it? Anyone else have questions, or concerns about the timing and size of these recent grants, particularly considering their abysmal performance in all areas over the past 12 months? Who wouldn't want a job where there are no expectations and lavish rewards. Maybe that's fine for a private company, but not for a public company unless the shareholders allow it. A theft has occurred IMO.

  • Reply to

    What's going on?

    by afro_bro_bro Jul 20, 2014 6:53 PM
    bioimmunomabman bioimmunomabman Jul 21, 2014 8:37 AM Flag

    management had their cheap shares awarded, now it can go up. It's time for this irresponsible, unresponsive, rubber-stamp BOD to be replaced. The performance of IMGN over the past 12 months has been terrible based on any reasonable evaluation, 1) stock price 2) pipeline advancement 3) Bus Dev... With the exception of the research team, execs should have not earned option awards and in fact, Junius and some other execs would have been fired by a company with reasonable standards/requirements for job performance IMO.

    How can shareholders remove the irresponsible IMGN BOD and stop the execs and BOD from stealing IMGN from the shareholders? I see a few options, 1) acquisition, 2) attracting the buying attention of a large shareholder activist, or 3) unite the largest current shareholders against the execs and board.

  • Reply to

    revenue from ovarian orphan drug status from FDA?

    by my_daddie Jul 15, 2014 3:29 PM
    bioimmunomabman bioimmunomabman Jul 18, 2014 1:13 PM Flag

    this is effing criminal and an outrage. Please let the company know about it.

  • Reply to

    How to kill a snake

    by eviljoe2013 Jul 18, 2014 10:49 AM
    bioimmunomabman bioimmunomabman Jul 18, 2014 11:14 AM Flag

    not so far it seems their plan is working well, much to our demise. They are exiting in an orderly fashion and seemingly at a profit for most of their shares in a sharply rising market. They are evil and I wish them suffering, at least in a financial sense, but so far it's not happening.

  • bioimmunomabman bioimmunomabman Jul 18, 2014 10:33 AM Flag

    It should be clear by now that ARNA is being opposed by well funded, well connected criminals. The sooner they exit the better. Maybe then the stock price can go up for a change. For today watch the crooks work the $5 close for opex.

  • bioimmunomabman bioimmunomabman Jul 18, 2014 10:21 AM Flag

    I don't recall any such discussions, so how can there be "no more' when there never was? Not that I don't agree Cramer and his sham of a company TSC and AF are working against ARNA and for the hedge fund shorts. One day they will be investigated and convicted IMO. Anyway, great growth in the numbers will one-day pay off.

  • Reply to

    Symphony #'s from John Galt on IV

    by simplyincome Jul 18, 2014 9:45 AM
    bioimmunomabman bioimmunomabman Jul 18, 2014 9:58 AM Flag

    How is the stock not flying on this news? $5 close for the market criminals opex today?

  • Reply to

    revenue from ovarian orphan drug status from FDA?

    by my_daddie Jul 15, 2014 3:29 PM
    bioimmunomabman bioimmunomabman Jul 17, 2014 9:03 PM Flag

    I am making every effort to put IMGN into play, or get it on the radar screen that a person of my "size" can do. I believe in shareholder rights as owners and that management's first job is to improve the stock price, which IMGN management has failed to do. There's too much LT value and potential for IMGN to be trading at this price level. I believe the main reason for the low valuation, or gap with SGEN is lack of belief in the credibility and decision making of IMGN's executive management team. The research team is fantastic, the phase I team is fine, technology is great, patents and NOL's have value. It's poor leadership, lack of Business Dev, weak IR/PR strategy, poor decisions/execution in mid to late development, Sr. executives/ nsider greed and selling...that is killing our value. I remain hopeful, but have lost all trust and patience.

  • Reply to

    When was the last time you hired a CFO?

    by crecy_war_knight Jul 17, 2014 1:21 PM
    bioimmunomabman bioimmunomabman Jul 17, 2014 4:49 PM Flag

    the poster clearly does not understand the difference between options and shares...

  • Reply to

    When was the last time you hired a CFO?

    by crecy_war_knight Jul 17, 2014 1:21 PM
    bioimmunomabman bioimmunomabman Jul 17, 2014 4:47 PM Flag

    Pfeffer is a terrible CFO, he allowed CELG to hold 80% of their assets in a phase II spin off that was once valued at 800MM then crashed to about $200MM when it was acquired. I warned him on multiple occasions that he and the dopey CEO were being irresponsible. These guys are all overpaid IMO unless they bring something to the table, wall street contacts, bus dev contacts, etc. The good news is that under $20.77 the options on those 320,000 shares are worthless, so he better hope for success.

11.30+0.16(+1.44%)Sep 17 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.